64Cu MeCOSar Octreotate - Clarity Pharmaceuticals

Drug Profile

64Cu MeCOSar Octreotate - Clarity Pharmaceuticals

Alternative Names: 64-Cu-SARTATE; copper-64 labelled MeCOSar-Tyr3-octreotate; SARTATE™ KIDS PET imaging - Clarity Pharmaceuticals; SARTATE™ NETs PET imaging - Clarity Pharmaceuticals; SARTATE™ PET imaging - Clarity Pharmaceuticals

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clarity Pharmaceuticals
  • Class Diagnostic agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours
  • Phase 0 Neuroblastoma

Most Recent Events

  • 26 Sep 2017 Clarity Pharmaceuticals completes the phase IIa trial in Neuroendocrine tumours (Diagnosis) in Australia before September 2017 (Clarity Pharmaceuticals pipeline, September 2017)
  • 31 Aug 2017 Clarity Pharmaceuticals plans a phase I SARTATE™ Kids trial for Neuroblastoma (Diagnosis, In infants, In children, In adolescents) in Australia in September 2017 (ACTRN12617001259336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top